APRINOIA Therapeutics宣布APN-1607获得美国FDA授予快速通道认定用于诊断进行性核上性麻痹
21. Mai 2024 20:00 ET
|
APRINOIA Therapeutics, Inc.
马萨诸塞州剑桥, May 22, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc.（“APRINOIA”或“公司”），专注于开发神经退行性疾病的新颖治疗和精确诊断方法的临床阶段生物制药公司，今天宣布，美国食品药品监督管理局（FDA）于2024年5月月8日授予正电子发射断层扫描（PET）示踪剂APN-1607（florzolotau...
APRINOIA Therapeutics進行性核上性麻痺の診断薬APN-1607の 米国FDAによるファストトラック指定を発表
21. Mai 2024 20:00 ET
|
APRINOIA Therapeutics, Inc.
マサチューセッツ州ケンブリッジ , May 22, 2024 (GLOBE NEWSWIRE) --...
APRINOIA Therapeutics宣佈APN-1607獲得美國FDA授予快速審查認定用於診斷進行性核上性麻痹
21. Mai 2024 20:00 ET
|
APRINOIA Therapeutics, Inc.
麻塞諸塞州劍橋, May 22, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc.（“APRINOIA”或“公司”），以開發神經退行性疾病的新穎治療和精確診斷方法為主的臨床階段生物製藥公司，今天宣佈，美國食品藥品監督管理局（FDA）於2024年5月月8日授予正電子發射斷層掃描（PET）示蹤劑APN-1607（florzolotau...
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy
21. Mai 2024 20:00 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision...
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
20. Mai 2024 08:00 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“Aprinoia” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision...
APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)
11. September 2023 07:00 ET
|
APRINOIA Therapeutics, Inc.
Investment Supports APRINOIA’s Effort to Bring Precision Medicine to Neuroscience, Advancing APRINOIA’s Diagnostic and Therapeutic PipelinesFunding Supports APRINOIA’s Goal to Bring a Central Nervous...
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
28. August 2023 11:00 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
23. August 2023 17:21 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...